Aslan Pharmaceuticals Ltd Adr (ASLN) has released an update.
ASLAN Pharmaceuticals Ltd Adr has announced promising interim results from their Phase 2 TREK-DX study, showing that eblasakimab is effective in atopic dermatitis (AD) patients who previously did not respond to dupilumab. The data, to be discussed at a virtual KOL event, reveals significant patient improvements, including a reduction in EASI scores and itchiness, with a notably rapid onset of effect. This positions eblasakimab as a potential new treatment option for this subset of AD patients, with full study data expected later in the year.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.
